THERAtRAME
ULiège

THERAtRAME

Biotech
Biotech
Biotech
Biotech

THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer.

Cancer is the second most common cause of death worldwide. Even though great advances have been made in the last decades, the current therapeutic options are still poorly effective for a large portion of cancer patients. Poor response and development of resistance to therapy are the main cause of current cancer treatment failure, resulting in an urgent need for groundbreaking therapeutic solutions.

THERAtRAME has developed an innovative discovery platform to create and develop novel therapeutic agents to beat untreatable or resistant cancers. The company is building on the pioneering discoveries of its founders to develop first-in-class drugs targeting the tRNA epitranscriptomics. Their approach integrates hardcore drug discovery activities with unique proprietary screening technologies and AI-based mathematical models to exploit the potential of tRNA epitranscriptomics as a transversal target space in oncology.

No items found.

THERAtRAME is a spin-off company of the University of Liège (ULiège) and WELBIO that aims to translate the breakthrough discoveries made by its founders on the importance of tRNA epitranscriptomics in cancer into novel therapeutic strategies. This pioneering work results from over a decade of fundamental research performed at ULiège, with the support of WELBIO, the Belgian Foundation against Cancer and FNRS. The founder team was able to attract key business profiles and investors to guide the translation of its cutting-edge science into concrete solutions for the benefit of patients.

THERAtRAME has the ambition to become the world leader in providing and positioning new therapeutics against tRNA epitranscriptomics. Its unique platform approach has the potential to strongly contribute to major advances in cancer therapy by partnering with prominent pharma actors in oncology.

Sara Vandenwijngaert

Sara Vandenwijngaert

Junior Partner Qbic II & III

This company is aligned with the following SDGs

Good health and well-being
Good health and well-being
QustomDot
Qbic II
Deeptech
Deeptech
Deeptech
Deeptech

QustomDot

QustomDot is developing cadmium-free quantum dots that are stable enough for advanced applications.

Universiteit Gent
moveUP
Qbic II
HealthTech
HealthTech
HealthTech
HealthTech

moveUP

moveUP develops personalized remote digital care for patients undergoing surgery and other interventions.

AZ Maria Middelares
VUB
Indigo
Qbic I & II
HealthTech
HealthTech
HealthTech
HealthTech

Indigo

Indigo is developing an implantable sensor that allows to continuously measure glucose and other metabolites for up to two years.

Universiteit Gent
imec